Antiviral natural products based on targeting SARS-CoV-2 enzymes: trends and perspectives
Dae-Geun Song1,2,*, Md Sofequl Islam Mukim1,2, Keunwan Park1, Hee-Ju Lee1, Jaeyoung Kwon1,2, Wook-Bin Lee2,3, Moon-Hyeong Seo3, and Cheol-Ho Pan1,2
1Center for Natural Product Systems Biology, KIST Gangneung Institute of Natural Products, 2Natural Product Applied Science, KIST School, University of Science and Technology, 3Center for Natural Product Efficacy Optimization, KIST Gangneung Institute of Natural Products
Correspondence to: *Dae-Geun Song
Center for Natural Product Systems Biology, KIST Gangneung Institute of Natural Products, Gangneung, 25451, Korea
Tel: +82-33-650-3658
E-mail: dsong82@kist.re.kr
Center for Natural Product Systems Biology, KIST Gangneung Institute of Natural Products, Gangneung, 25451, Korea
Tel: +82-33-650-3658
E-mail: dsong82@kist.re.kr
Received October 28, 2024; Revised November 9, 2024; Accepted November 11, 2024.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Abstract
- Natural products have long played a pivotal role in the treatment of human diseases, contributing to approximately 80% of drugs in the current market. Recently, with the global COVID-19 pandemic, interest in plant-derived compounds as antiviral agents has surged. This review focuses on the potential of natural compounds targeting SARS-CoV-2 enzymes, particularly RNA-dependent RNA polymerase (RdRp) and main protease (Mpro). Various plant-based secondary metabolites, including flavonoids, polyphenols, and isothiocyanates, have shown inhibitory activity against these viral targets. While compounds like baicalein, myricetin, and curcumin have demonstrated moderate efficacy in vitro, their clinical application faces challenges such as bioavailability and potency. Enhancements through structural modification, nanotechnology, and combination therapy are strategies to increase the antiviral potential of these compounds. This review provides an overview of key natural inhibitors of SARS-CoV-2 enzymes, Mpro or RdRp, underscoring their promise and the remaining challenges for developing effective natural product-based antiviral therapies.
- Keywords : natural product, SARS-CoV-2, main protease, RNA-dependent RNA polymerase, antivirals
Full Text(PDF) Free
